A. Kalykaki

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

John Souglakos, N. Androulakis, K. Syrigos et al. · British Journal of Cancer · 2006 · 403 citations · Full text

Medicine, Oncology, Pharmacology +15

Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients

Galatea Kallergi, Sofia Agelaki, A. Kalykaki et al. · Breast Cancer Research · 2008 · 151 citations · Full text

Medicine, Cell Biology, Oncology +17

Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study

Christos Emmanouilides, G. Sfakiotaki, Nikolaos Androulakis et al. · BMC Cancer · 2007 · 102 citations · Full text

Medicine, Oncology, Pharmacology +14

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse

Emmanouil Saloustros, Maria Perraki, Stella Apostolaki et al. · Breast Cancer Research · 2011 · 83 citations · Full text

Medicine, Oncology, Breast Oncology +15

Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance

Stella Apostolaki, Maria Perraki, Athanasios Pallis et al. · Annals of Oncology · 2007 · 82 citations · Full text

Medicine, Molecular Medicine, Oncology +15